These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1151 related articles for article (PubMed ID: 15955905)

  • 21. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
    Hirakawa T; Yamaguchi H; Yokose N; Gomi S; Inokuchi K; Dan K
    Ann Hematol; 2010 Sep; 89(9):897-904. PubMed ID: 20414658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
    Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffuse large B-cell lymphoma.
    Ng AK
    Semin Radiat Oncol; 2007 Jul; 17(3):169-75. PubMed ID: 17591563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
    Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
    Lin PC; Hsiao LT; Poh SB; Wang WS; Yen CC; Chao TC; Liu JH; Chiou TJ; Chen PM
    Ann Hematol; 2007 Feb; 86(2):95-100. PubMed ID: 17031689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
    Li JM; Wang L; Shen Y; Xia ZG; Chen Y; Chen QS; Chen Y; Zeng XY; You JH; Qian Y; Shen ZX
    Ann Hematol; 2007 Sep; 86(9):639-45. PubMed ID: 17572895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
    Song MK; Chung JS; Sung-Yong O; Lee GW; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ; Shin DH; Yun EY
    Ann Hematol; 2010 Oct; 89(10):985-91. PubMed ID: 20428871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
    Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
    Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
    Biswas T; Dhakal S; Chen R; Hyrien O; Bernstein S; Friedberg JW; Fisher RI; Liesveld J; Phillips G; Constine LS
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):79-85. PubMed ID: 19647953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma.
    Morrison VA
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1651-8. PubMed ID: 18925856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
    Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
    Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
    Samaras P; Heider H; Haile SR; Petrausch U; Schaefer NG; Siciliano RD; Meisel A; Mischo A; Zweifel M; Knuth A; Stenner-Liewen F; Renner C
    Ann Hematol; 2010 Aug; 89(8):783-7. PubMed ID: 20204361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
    Schneider T; Molnár Z; Deák B; Várady E; Tóth E; Csomor J; Matolcsy A; Lovey J; Lengyel Z; Petri K; Gaudi I; Rosta A
    Orv Hetil; 2009 Nov; 150(44):2019-26. PubMed ID: 19861288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
    Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
    Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.
    Yoon DH; Choi DR; Ahn HJ; Kim S; Lee DH; Kim SW; Park BH; Yoon SO; Huh J; Lee SW; Suh C
    Eur J Haematol; 2010 Aug; 85(2):149-57. PubMed ID: 20477862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standard treatment of advanced-stage diffuse large B-cell lymphoma.
    Coiffier B
    Semin Hematol; 2006 Oct; 43(4):213-20. PubMed ID: 17027655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.